MARKET WIRETradingView • 17h ago
Aethlon Medical, Inc. Estimates – NASDAQ:AEMDTradingView report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.
Why AEMD Stock slipped -1.45% Today — RQD Quant Desk Flash
$5.44 -1.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.42
Aethlon Medical Inc. (AEMD) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $8.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AEMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AEMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Aethlon Medical Inc. (NASDAQ: AEMD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $5.44 (-1.45% 1D, market cap $8.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AEMD ranks #580 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AEMD compare to NMTC and PLSM in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), AEMD carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NMTC (NeuroOne Medical Technologies Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $8.4M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, AEMD leads on earnings multiple (N/A) while AEMD leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AEMD?
▼
Per AEMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0000882291), Aethlon Medical Inc. generated $0 in revenue, -$7.2M in net income, and -$7.0M in free cash flow against $8.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.42 (-0.45%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AEMD)Realized 20D OHLCV Swing Band: ±11.7%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY AEMD SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (25% of score)
FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 53.2 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$5.58-4.8% Next Q
44
Q2 (-2Q)Grade D$5.31-4.5% Next Q
41
Q3 (-1Q)Grade E$5.07+7.3% Next Q
39
CurrentGrade D-$5.44-8.3% Hist 90D α
36
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a AEMD Turnaround Squeeze
While AEMD currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.58) and Max Pain ($5.71) forces dealer call-delta covering toward $27.51.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AEMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AEMD Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AEMD Stock slipped -1.45% Today — RQD Quant Desk Flash
Aethlon Medical Inc. (AEMD) slipped -1.45% to $5.44, trading at 16% of its 52-week range ($1.41 – $26.2). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 16% of its 52-week range ($1.41 – $26.2) with RSI-14 at 53.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.7% around $5.44 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live AEMD Headlines & Catalysts
MARKET WIREYahoo Finance UK • 20h ago
Aethlon Medical, Inc. (AEMD) Seasonal returns chartYahoo Finance UK report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 23h ago
Two Jane Street subsidiaries report stakes in Aethlon Medical (AEMD).Stock Titan report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com India • 1d ago
Form 4 Aethlon Medical Inc: Angela Rossetti (Director) For: 17 April By Investing.comInvesting.com India report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com UK • 1d ago
Form 4 Aethlon Medical Inc: Edward G. Broenniman (Director) For: 30 SeptemberInvesting.com UK report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Aethlon Medical (AEMD) Edges Up 0.19% to $5.16, Sitting Midway Between Support and Resistance - RVOL Spikehttps://www.siam.in/ report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.dars.gov.et/ • 1d ago
AEMD Q3 2026 Earnings: Loss Per Share Misses Consensus by a Wide Margin - Diluted EPS Reporthttps://www.dars.gov.et/ report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.dars.gov.et/ • 1d ago
AEMD Q3 2026 Earnings: Wider-Than-Expected Loss With No Revenue Figure Provided - Revenue Miss Reporthttps://www.dars.gov.et/ report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AEMD)
- ✓Walkthrough of AEMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AEMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -54.67%▼ DESCENDING CHANNEL
2026-11-03O $5.52H $5.52L $5.44C $5.44VOL 27.7K
RES: $6.79SUP: $0.22SMA50: $4.58SMA200: $7.69
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AEMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AEMD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AEMD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AEMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AEMD)
Health Care Rank #580 of 1016
⚔️ NMTC vs AEMD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AEMD vs. NMTC, PLSM, FEMY, ICU)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Aethlon Medical Inc. (AEMD) ranks #580 by composite RQD confidence (36/100, grade D-) and #905 by equity capitalization ($8.7M). Within this direct 5-issuer industry benchmark cohort, AEMD leads on earnings valuation at N/A trailing P/E, while AEMD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PLSM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with AEMD at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AEMD
ACTIVE
Aethlon Medical Inc. | D- | 36/100 | — | — | -35.0% | -1.45% | $8.7M | Benchmark Subject |
| NMTC NeuroOne Medical Technologies Corporation | E | 33/100 | — | 56.5% | -35.0% | -4.39% | $8.4M | /nmtc-vs-aemd → |
| PLSM Pulsenmore Ltd. | D | 47/100 | — | — | — | +3.09% | $10.9M | /plsm-vs-aemd → |
| FEMY Femasys Inc. | E | 30/100 | — | 62.0% | -35.0% | +1.11% | $11.5M | /femy-vs-aemd → |
| ICU SeaStar Medical Holding Corporation | E | 31/100 | — | 95.7% | -35.0% | -3.03% | $11.8M | /icu-vs-aemd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0000882291In its most recent audited fiscal period (FY2025, filed 2026-03-31), Aethlon Medical Inc. (AEMD) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$7.2M, operating cash flow of -$7.0M, and free cash flow of -$7.0M (+8.4% YoY). On the balance sheet, AEMD closed FY2025 with $8.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-03-31 | $0 | -$7.2M | -$7.0M | -$7.0M | $8.1M | — |
| FY2024 (FY) | 2025-03-31 | $0 | -$13.4M | -$7.6M | -$7.6M | $6.5M | — |
| FY2023 (FY) | 2024-03-31 | $0 | -$12.2M | -$10.1M | -$10.1M | — | — |
3. AEMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AEMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Aethlon Medical Inc. (NASDAQ: AEMD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $5.44 (-1.45% 1D, market cap $8.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AEMD ranks #580 in composite RQD confidence.
How does AEMD compare to NMTC and PLSM in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), AEMD carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NMTC (NeuroOne Medical Technologies Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $8.4M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, AEMD leads on earnings multiple (N/A) while AEMD leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AEMD?
Per AEMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0000882291), Aethlon Medical Inc. generated $0 in revenue, -$7.2M in net income, and -$7.0M in free cash flow against $8.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AEMD trading relative to its 50-day, 200-day, and 52-week technical levels?
AEMD last traded at $5.44 (-1.45% on volume of 27,685 shares), positioning the stock +18.78% above its 50-day simple moving average ($4.58) and -29.26% below its 200-day simple moving average ($7.69). Across its 52-week range of $1.41 to $26.20, AEMD sits at the 16.3% percentile with a 14-day RSI of 53.2 (NEUTRAL RANGE) and an implied next-earnings move of ±11.7% ($4.80 to $6.08).
AEMD Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AEMD stock moving today?
Why AEMD Stock slipped -1.45% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 36/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
AEMD — Aethlon Medical Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:52:09Z
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD score is 38 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow" (per the Roarable RQD rating). Across its five pillars:
- Fundamental Cash Engine: 5 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of 0%. For an investor, this means the business is not currently generating returns on capital or free cash flow; valuation cannot rest on earnings or cash yield.
- Whale 13F Flow: 9 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is below midpoint, so institutional support signals are weak in the source data.
- Insider Conviction: 5 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. A low score indicates insider activity does not provide a strong conviction signal.
- Macro Regime Fit: 9 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity considered. A neutral beta combined with a low score means the stock offers no clear macro tailwind in the framework.
- Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. This is the strongest pillar, but still sub-50%, indicating balance-sheet fragility.
Investor implications: the upside case depends on a turnaround in operating cash generation, which the current data does not show. The valuation tradeoff is that the stock trades at a $8.9M market capitalization with negative ROIC, so price action is not anchored by reported earnings. The low pillar scores in cash engine, flow, and insider conviction point to limited near-term confirmation for a recovery thesis. This is an analytical summary, not personalized advice.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-7.3M | $-7.2M | N/A | $-7.0M | $7.0M | N/A |
| FY 2024 | $0.0M | $-9.3M | $-13.4M | N/A | $-7.6M | $4.8M | N/A |
| FY 2023 | $0.0M | $-12.6M | $-12.2M | N/A | $-10.1M | N/A | N/A |
Per the SEC financials, the company reported no revenue and operating losses in each period shown, with gross, operating, and net margins all at 0% per the market data. Per the market data, ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity of 0.5. Cash reported at $7.0M for FY 2025 compared with $4.8M for FY 2024, while operating losses narrowed from $-9.3M to $-7.3M over that span.
Open Questions
- What specific products or revenue streams, if any, generate the company's income given $0.0M reported revenue?
- What is the cash runway implied by FY 2025 cash of $7.0M against operating losses of $-7.3M?
- What are the terms, size, and direction of the Form 4 transactions and the Jane Street subsidiary stake disclosures?
- Why do market-cap figures differ between the profile ($0.0B) and market data ($8.9M), and which is correct?
- What is the debt structure behind the reported Debt/Equity of 0.5 when debt is listed as N/A in every period?
AEMD Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Aethlon Medical Inc. (AEMD) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 17h ago
Aethlon Medical, Inc. Estimates – NASDAQ:AEMD TradingView report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance UK • 20h ago
Aethlon Medical, Inc. (AEMD) Seasonal returns chart Yahoo Finance UK report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 23h ago
Two Jane Street subsidiaries report stakes in Aethlon Medical (AEMD). Stock Titan report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com India • 1d ago
Form 4 Aethlon Medical Inc: Angela Rossetti (Director) For: 17 April By Investing.com Investing.com India report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com UK • 1d ago
Form 4 Aethlon Medical Inc: Edward G. Broenniman (Director) For: 30 September Investing.com UK report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Aethlon Medical (AEMD) Edges Up 0.19% to $5.16, Sitting Midway Between Support and Resistance - RVOL Spike https://www.siam.in/ report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago
AEMD Q3 2026 Earnings: Loss Per Share Misses Consensus by a Wide Margin - Diluted EPS Report https://www.dars.gov.et/ report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago
AEMD Q3 2026 Earnings: Wider-Than-Expected Loss With No Revenue Figure Provided - Revenue Miss Report https://www.dars.gov.et/ report covering Aethlon Medical Inc. (AEMD) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
AEMD Bull vs. Bear Conversation Board — What's Your Call at $5.44?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AEMD 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $4.86 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is AEMD (D- • RQD 38/100) a Buy at $5.52?
Welcome to the AEMD (Aethlon Medical Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $4.20 (-23.9%)
Spot @ $5.52 Pump the brakes on AEMD — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on AEMD, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Aethlon Medical Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $6.46 (+17.0%)
Spot @ $5.52 AEMD cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on AEMD, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $5.52 (52-wk range $1.41 - $26.90), any beat on forward guidance forces shorts and underweight funds to chase.